Abeona Therapeutics Inc.
ABEO
$4.79
$0.194.13%
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Revenue | 147.52% | -17.90% | -17.90% | -68.08% | -52.87% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 147.52% | -17.90% | -17.90% | -68.08% | -52.87% |
| Cost of Revenue | 4.59% | -38.41% | -52.79% | -62.09% | -53.44% |
| Gross Profit | 7.57% | 41.81% | 57.11% | 61.56% | 53.49% |
| SG&A Expenses | 10.13% | 18.17% | 3.95% | -13.14% | -20.34% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 10.78% | -2.43% | -15.19% | -27.42% | -22.69% |
| Operating Income | -6.50% | 1.01% | 14.97% | 25.04% | 21.11% |
| Income Before Tax | -36.51% | 43.58% | 50.77% | 70.59% | 53.26% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -36.51% | 43.58% | 50.77% | 70.59% | 53.26% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -36.51% | 43.58% | 50.77% | 70.59% | 53.26% |
| EBIT | -6.50% | 1.01% | 14.97% | 25.04% | 21.11% |
| EBITDA | -8.89% | -0.37% | 15.11% | 25.99% | 22.09% |
| EPS Basic | 61.37% | 85.72% | 83.45% | 83.42% | 68.31% |
| Normalized Basic EPS | 48.66% | 69.74% | 73.10% | 78.99% | 66.86% |
| EPS Diluted | 61.37% | 85.72% | 83.45% | 83.42% | 68.31% |
| Normalized Diluted EPS | 48.66% | 69.74% | 73.10% | 78.99% | 66.86% |
| Average Basic Shares Outstanding | 171.68% | 229.28% | 177.78% | 139.41% | 99.66% |
| Average Diluted Shares Outstanding | 171.68% | 229.28% | 177.78% | 139.41% | 99.66% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
